๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
iRhythm Holdings, Inc. (IRTC)
NASDAQ: IRTC ยท Real-Time Price ยท USD
94.24
-0.63 (-0.66%)
At close: Nov 19, 2026, 4:00 PM EST
98.05
+3.81 (4.04%)
After-hours: Nov 19, 2026, 5:39 PM EST
โ† View all transcripts

Jefferies Global Healthcare Conference

Nov 19, 2026

Summary

Growth plans center on primary-care expansion, MCT share gains with VitalConnect, and adjacent markets. Q3 revenue reached $221.6 million with 23.1% adjusted EBITDA margin; Q1 2027 is targeted for the VitalConnect commercial launch.

Matthew Aspro
Senior Associate and US Medtech Equity Research, Jefferies

Good morning, everyone. Welcome to the final day of the Jefferies London Healthcare Conference. My name is Matthew Aspro, and I work on our U.S. MedTech team, and today I am joined by Daniel Wilson, the CFO of iRhythm. We are just going to kick this off with a presentation today. Thank you.

Daniel Wilson
CFO, iRhythm Technologies

Great. Thank you, Matt, and good to see you all. Thanks for the time today. This year, iRhythm is celebrating 20 years as an operating company, 10 years as a public company, so a true milestone for the company. In that time period, iRhythm has become the standard of care and really have changed how patients are getting diagnosed with cardiac arrhythmias. Looking forward, we have equally grand ambitions. Really want to point you to three primary growth objectives for the company, and the first being continued market expansion in long-term continuous monitoring. That is with our market-leading position with Zio Monitor, the standard of care today. We see a real opportunity to continue to expand that market as we move into primary care, and we will talk through that. The second one I want to point folks to is the opportunity in the MCT segment.

We are 15% share today, now 20% with our VitalConnect acquisition. We believe we have a best-in-class portfolio and can be the market leader in that segment over time. Then third, leveraging the platform we have built over the last 20 years to move into adjacent markets. Really want to orient investors to those three opportunities, and you will see those as I go through the presentation today. I will be making forward-looking statements, like the one I just made, so refer folks to our SEC filings for full disclosure of risk factors. If we think about where iRhythm is focused and the problems we are trying to solve, I would say iRhythm is really well-aligned with overall themes within the market and big opportunities to make an impact. First, heart disease remains the number one cause of death globally.

It continues to grow as our population ages, and a real opportunity to continue to drive an impact there. It is a costly disease. Patients are regularly showing up in the emergency room, urgent care, and there is an opportunity to diagnose these patients earlier in their care journey, avoid those downstream costs, avoid those clinical events that land patients in the emergency room and urgent care. There are several market catalysts that are working in our favor as there is a shift to preventative and predictive medicine, a shift to value-based care that plays to our strengths. We are benefiting from those tailwinds today and believe we are in the early innings of those tailwinds. There are constraints in terms of access for patients. If you think about cardiologists, only 46% of U.S. counties have a cardiologist.

Only 46% of U.S. counties don't have a cardiologist, including 86% of rural counties, so it is concentrated in urban centers, and access is difficult for patients. The move is really shifting healthcare outside of the four walls of the hospital. Again, this plays to our strength. We can meet the patient at their point of care in their home and avoid, again, these downstream impacts. As you think about what we've built over the last 20 years, it's really a platform, and the platform is really our competitive moat to continue to drive penetration in our core markets, but also serves as that foundation to move into adjacent market opportunities. We are more than just a device company, and that's important, and I think investors understand that.

It's really device, data, and services together, and that's an incredibly valuable platform and valuable asset that not only establishes that competitive moat, but again, allows us for opportunities to grow into adjacent markets. On the device side, with our Zio Monitor wearable there, an incredible form factor, patient-friendly, can wear it for 14 days, can continuously go about their normal day-to-day lives, can shower, sleep, exercise, just a really, really solid patient experience, capturing on average 1.5 million heartbeats in those 14 days. To draw the insights out of that data that we're capturing with the device, it really requires sophisticated AI tools, and we've built those tools over the last 20 years.

We have a third-generation algorithm that is FDA cleared that we'll be launching into commercial production next year, and that allows us to deliver our service at scale efficiently and draw out the clinical insights that are relevant for patients and physicians. We do that all seamlessly by integrating into our customer workflows digitally. So we have our Zio Suite digital solution, but also EHR integrations. Over 60% of our volume comes through EHR integrations. Being clinical superior is important, but being operationally complete and seamless in clinical workflows is as important, and we've built that aspect of our platform over the last 20 years as well. Again, we see our platform not only as our competitive moat to continue to gain share in the market, be a leader in the market we're serving today, but also as a platform to move into adjacent market opportunities over time.

In terms of the scale that we've reached, so now serving close to 3 million patients per year. In our history, we've served over 14 million patients. That has allowed us to amass a dataset of over 3 billion hours of curated ECG data. That allows us to train the AI tools that I mentioned on the prior page, and really scale is starting to become a competitive advantage for us. In the third quarter, we delivered $221.6 million in revenue, growth of around 15%. Importantly, our profitability is really starting to show up in a big way, 23.1% adjusted EBITDA margin in the quarter. That's over 1,100 basis points of improvement year-over-year. So, really starting to demonstrate the operating leverage inherent in our business.

As we think about the opportunity going forward, we continue to point to a patient opportunity of 27+ million patients in the U.S. that could benefit from cardiac monitoring. That is versus a market today that is only 7 million tests. So, a real opportunity to continue to expand the overall market. These are patients that have symptoms in their medical record, that are candidates for cardiac monitoring, that are indicated for cardiac monitoring, but they're not being monitored today. This slide illustrates what that market opportunity looks like today. Globally, we see the ACM market around 10 million tests, believe it can grow to 30 million tests over time, and it's really that 27 million patient opportunity that leads to that 30 million test opportunity. Again, these are patients that are showing up today with symptoms, but are not associating their symptoms with cardiac arrhythmias.

The key to opening up that market opportunity is the move into primary care, and we've been seeing that move into primary care over the last several years. We have been pushing into primary care from a market standpoint and really doing that in two ways. One, a land and expand model. So we generally will open up an account with cardiology or electrophysiology as that clinical champion, and then over time move upstream into primary care. Cardiologists and electrophysiologists, they're supporting that move into primary care. They want to see patients that are already qualified. They don't want to see a patient just to prescribe Zio and then realize they don't actually need to see that patient. So they're supporting this move into primary care. That's the land and expand model. Second, we have a part of our business called the innovative channel.

These are large national regional primary care groups, ACOs, value-based care groups that recognize the benefit of proactive monitoring, and we're seeing that part of the business grow really nicely over the last two, three years. That has grown to mid-single digit % of our revenue. Believe we're still really early innings there, and we'll see that as a nice growth driver, durable growth driver for the business, and that is moving into that 27 million patient opportunity. Importantly, the value proposition that these innovative channel partners are signing up for, it is, "I'm going to proactively monitor my patients. I'm going to find undiagnosed arrhythmias, and I'm going to prevent urgent care visits, ER visits, and save on those downstream costs." We are seeing that value proposition play through with our partners.

Every innovative channel partner we've launched to this point continues on monitoring today, and every partner we've gotten to a pilot stage has continued on to a full commercial program. That tells you the value proposition is playing through. We are working on clinical and economic evidence, real-world evidence with our partners. We'll see that come to market in the coming months and quarters. Believe that can be another catalyst to continue to open up that side of the market. Internationally, we see that as a growth opportunity as well. It's a small part of our business today, low single-digit % of revenue. Really have presence in six countries, the U.K. being our most developed country. We've been commercial here for several years now. Within Western Europe, we launched into four countries over the last two years, and then in Japan more recently, have commercially launched there.

That is the second-largest market opportunity globally with 1.6 million tests in Japan. We are running a head-to-head study now to work towards premium reimbursement in Japan. We have reimbursement established today that is more in line with traditional Holter monitoring. We do not believe that recognizes the full value that Zio brings with long-term continuous monitoring. We are running that head-to-head study to establish premium reimbursement. I would like to spend a minute now talking about our VitalConnect acquisition, one we are really excited about. It is a company we have followed for several years and always felt like the technology was compelling and would be a nice complement to the iRhythm business.

Over the last several years, VitalConnect has made great progress from a gross margin standpoint, some of the clinical infrastructure on the back end that was important for us to see develop, and then on our side, really working to get the core business to a place where we could absorb an acquisition and confidently execute on an acquisition. We were pleased that we saw alignment in those two regards earlier this year. We announced the acquisition in early August, closed ahead of schedule in early October, and the thesis is really quite simple. It is combining VitalConnect's MCT platform, primarily on the MCT side, that we believe is differentiated and unique, together with our commercial infrastructure, our operational infrastructure, as well as our Zio AT product to have a best-in-class MCT portfolio.

Really excited about integrating VitalConnect into the product portfolio, into the company, and fully launching this in Q1 next year. Making very good progress on those integration efforts, as well as the commercial training. We have had our commercial team trained over the last couple of weeks, initial training with our full global sales meeting scheduled for Q1 next year. We are seeing really good progress, and the thesis really is we have 72% share on long-term continuous with Zio Monitor, but only 15% share on the MCT side. There is a lot of our accounts where we have Zio Monitor business, we do not have the full business on the MCT side, and that is clear with the 72% share versus 15%. The idea is with a more complete MCT portfolio with VitalConnect, we can start winning that business.

We have seen good progress there, and actually over the last couple of weeks have won a couple of accounts that fit exactly that profile, where we have had the long-term continuous monitoring business, had not yet captured the MCT business with Zio AT, and were able to capture that business with VitalConnect. So exactly the thesis we were hoping to see play through. Of course, a lot more work to be done in terms of integration and getting our teams fully trained and going to full commercial launch in Q1 2027, but really encouraged by what we are seeing in the early days there. We get asked the question quite a bit in terms of how VitalConnect fits in the portfolio relative to Zio AT, which is our current MCT product. We are working on Zio MCT, which will be our next generation MCT product.

Really, we see the combination of the two as complementary and serving a complete portfolio that allows us to serve the complete MCT market. Think about Zio AT, ultimately Zio MCT, as that simple device, set it and forget it on the same platform as Zio Monitor, with that same wearable that patients can wear comfortably up to 14 days, eventually 21 days. That is important for certain patients, certain customers that have a high value on patient compliance, that set it and forget it simplicity does have real value in the market. We have proven that by getting to 15% share in that category with Zio AT. There is another part of the market where clinicians value other features, and the differentiated features that VitalConnect brings to the portfolio are really fourfold. One, up to 30 days of monitoring.

It can go up to 30 days, which is important to a number of physicians in the segment. They do that through multiple patches. A patient does need to swap out the patch four or five times to get out to 30 days, but importantly, clinicians have the option to monitor patients for up to 30 days with VitalConnect. Second, live look-in. Through the course of those 30 days, at any point in time, a clinician can go into VistaCenter, the VitalConnect platform, and look into the live data coming off of the VitalConnect product.

That is important when a patient is calling the physician, say, "I am feeling something," or they show up in the physician's office, there is an ability to immediately look into the data coming off of the patch and see it and make a clinical decision in that moment. That is the second aspect. The third, the four-in-one monitoring simplicity. The VitalConnect platform does have the ability to serve all four monitoring modalities. MCT, certainly, that is the majority of the revenue. Can also serve as an event monitor, long-term continuous monitor, as well as a short-term monitor, and that flexibility does really matter for certain physicians in the market. The last one I will point to is the multi-vitals. In addition to ECG, which is where Zio AT and Zio MCT are focused, VitalConnect rounds that out with additional vital signs.

That is respiratory rate, heart rate variability, fall detection. These are valuable insights for physicians and their patients, and that is another differentiating feature of the VitalConnect platform. Simplistically put together, we believe we have the best-in-class portfolio with Zio AT, ultimately Zio MCT, together with VitalConnect, and expect to be the market leader in the MCT category over time. On our Q3 call, just spend a minute here, showed good progress towards our overall strategies. I mentioned $221.6 million of revenue in the quarter. The 23.1% adjusted EBITDA margin played through nicely as well. A couple other things that we mentioned on the call that want to make sure investors are aware of. We submitted for pediatric indication with our Zio Monitor product. That is a nice point of evidence for innovation that we are investing in as a company.

Believe that can be a nice driver of the business going forward. Mentioned the CAMELOT-ALERT study, which showed Zio AT has a higher diagnostic yield relative to other MCT platforms. For investors that have followed our story for the last several years, you probably remember the CAMELOT data that was a real catalyst for growth with our Zio Monitor product. We are working to generate evidence similar to that with Zio AT and our MCT portfolio. This just visually shows where we landed on the quarter. Mentioned the revenue growth again, mid-teens growth. Importantly, that mid-teens growth is really on the backs of Zio Monitor. We did talk about a bit of disruption with our Zio AT product in the quarter, that we do expect to continue through the fourth quarter and potentially into 2027. But durable, consistent growth, stable growth with Zio Monitor.

On the gross profit side, saw a really nice healthy gross margin of 74.2%. There was 140 basis points of benefit there from a tariff refund that won't repeat, but normalizing for that, still really healthy gross margins and feel good about that continuing to expand over time. I did mention our third-generation algorithm going into commercial production next year, first half next year. That will be a nice lever for gross margin expansion going forward. We've estimated that will save us over $100 million in cumulative savings over five years, while we're able to leverage AI more and more and make the clinical service part of our business much more efficient and effective. Again, adjusted EBITDA margin mentioned 23.1%, showing the real operating power of the business.

For full-year outlook, we raised guidance to $890 million-$895 million for the year, adjusted EBITDA 15.5%-16%. I did mention the Zio AT disruption. We're expecting that to continue in the fourth quarter. Mentioned mid-teens growth for Zio Monitor expectation in Q4, and then we pointed to $16 million of contribution from VitalConnect. That's consistent with their current run rate. We're not expecting an acceleration of that business just yet. I mentioned full commercial launch early next year. We believe we're in a position to really expand our MCT share over time. We want to work through the integration, see those milestones play through, get our commercial team fully launched, and start seeing that show up in the business. But believe the framework is there, the opportunity is there to grow our share of the MCT category and really see nice growth acceleration.

VitalConnect has historically had 30 reps, 30 commercial reps. We're putting it now in the bag of our commercial team, call it 200 reps. There's a real opportunity to accelerate the growth there. Again, we want to see it play through before we start baking it into forward guidance. On our Q3 call, we did give some preliminary guidance around 2027, and really that framework is the same as what I just walked through as it relates to closing out 2026. Expect to see continued durable mid-teens growth with Zio Monitor that's benefiting from continued move into primary care. We're making investments into direct-to-patient awareness, making investments into primary care targeting and education and awareness to continue to open up that 27 million patient opportunity that I referenced earlier.

See a lot of growth opportunity there, continued growth opportunity there with Zio Monitor and expecting mid-teens growth next year. For Zio AT, kind of guiding investors to flat for the time being. We want to work through this period of disruption, get the two companies integrated, get our commercial teams trained, re-engage with our customers with that full product portfolio, and see AT growth kind of accelerate before we start baking that into forward guidance. With VitalConnect, expecting kind of consistent growth to what they've been delivering to this point. Very similarly, once our commercial teams are trained there, we have a team of 200 reps out selling VitalConnect, we should be able to outpace that. We want to see that play through.

We want to get through a couple of important milestones over the next several months here before we kind of rethink our forward expectations. On the profitability side, I will say next year, it's a focus on growth, making those investments into growth. That's VitalConnect, that's direct-to-patient marketing, the primary care expansion, other innovation that we're working on in addition to Zio MCT. We've guided investors to just above 15% adjusted EBITDA margin for next year. That is a target we committed to several years ago, feel really comfortable about delivering that. Then 2028 and beyond, there's an absolute opportunity to drive continued operating leverage as we shift a little bit and start to focus on the synergy opportunities within VitalConnect. There's a real opportunity to continue to drive operating leverage in the business.

One comment I'll make for investors, hopefully you all saw it, we did announce a $100 million accelerated share repurchase earlier this week. Believe in the fundamental value of the company and believe there's a bit of a disconnect at the time, and wanted to show that through some action with the profitability profile that we have been delivering, the liquidity profile, the free cash flow that we see ahead of us. We were comfortable using a bit of our liquidity to buy back some shares at these levels, while maintaining flexibility to continue to invest in the growth opportunities that we see ahead of us. I will wrap there. I appreciate the interest and the time today.

Great. Thank you very much.